A little more information:
"In a March 26th release from Exthera, its president and CEO Robert Ward NAE said, “We are very pleased to confirm the feasibility of Seraph 100 treatment of COVID-19. Since Seraph 100 treatments have also consistently produced improved oxygenation/lung function, we believe that this feature together with virus reduction may be a useful combination for treating COVID-19, while simultaneously treating the dangerous secondary infections that can occur in COVID-19 patients.”
Here’s how Seraph works. As a patient's blood flows through the Seraph filter, it passes over tiny beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body.
Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby removed from the bloodstream. Seraph does not add anything to the blood, which is returned to the patient with blood cells and proteins intact. Seraph targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection.
Seraph won Emergency Use Authorization from FDA for the treatment of COVID-19 in April, according to the company. "
www.mddionline.com/covid-19/dod-funds-clinical-trial-seraph-blood-filter-treat-covid-19
|